Seven Fleet Capital Management LP Has $510,000 Stake in Compass Therapeutics, Inc. $CMPX

Key Points

• Seven Fleet Capital Management cut its Compass Therapeutics stake by 75.2% in the second quarter, selling 707,472 shares and retaining 233,066 shares worth approximately $510,000, or 0.13% of the company.
• Other institutional investors increased exposure, including Vivo Capital and BVF, while BlackRock and Palo Alto Investors initiated new positions; institutions collectively own 68.43% of CMPX.
• CMPX shares opened at $2.38, near the lower end of their 52-week range. The company missed quarterly earnings estimates, but analysts maintain a “Moderate Buy” consensus with an average price target of $11.77.

Seven Fleet Capital Management LP reduced its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 75.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 233,066 shares of the company's stock after selling 707,472 shares during the period. Seven Fleet Capital Management LP owned about 0.13% of Compass Therapeutics worth $510,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in CMPX. BlackRock Inc. acquired a new position in Compass Therapeutics during the 2nd quarter worth approximately $24,707,000. Palo Alto Investors LP acquired a new stake in Compass Therapeutics in the second quarter valued at approximately $12,771,670. Vivo Capital LLC boosted its position in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. BVF Inc. IL grew its stake in shares of Compass Therapeutics by 63.5% during the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company's stock worth $41,697,000 after buying an additional 3,014,842 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Compass Therapeutics during the third quarter worth $9,892,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $2.38 on Friday. Compass Therapeutics, Inc. has a 52 week low of $1.61 and a 52 week high of $6.88. The firm has a market cap of $428.61 million, a PE ratio of -5.95 and a beta of 0.95. The firm's fifty day moving average is $2.22 and its 200-day moving average is $3.32.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). Sell-side analysts forecast that Compass Therapeutics, Inc. will post -0.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CMPX shares. Stifel Nicolaus set a $6.00 price target on Compass Therapeutics in a research note on Monday, June 1st. Wall Street Zen lowered Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Piper Sandler upped their target price on Compass Therapeutics from $4.00 to $6.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They issued a "buy" rating and a $5.00 target price for the company. Finally, Citigroup reissued a "market outperform" rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Compass Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $11.77.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.